@article{Rosas_I-2022_86743,
title = {Tocilizumab in patients hospitalised with COVID-19 pneumonia: efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)},
author = {Rosas, I. and Bräu, N. and Waters, M. and Go, R. and Malhotra, A. and Hunter, B. and Bhagani, S. and Skiest, D. and Savic, S. and Douglas, I. and Garcia-Diaz, J. and Aziz, M. and Cooper, N. and Youngstein, T. and Sorbo, L. and Zerda, D. and Ustianowski, A. and Gracian, A. and Blyth, K. and Carratalà, J. and François, B. and Benfield, T. and Haslem, D. and Bonfanti, P. and van der Leest, C. and Rohatgi, N. and Wiese, L. and Luyt, C. and Bauer, R. and Cai, F. and Lee, I. and Matharu, B. and Metcalf, L. and Wildum, S. and Graham, E. and Tsai, L. and Bao, M.},
month = {may},
year = {2022},
abstract = {Background: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown. Therefore, the efficacy and safety of tocilizumab in COVID-19 beyond day 28 and its impact on Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) clearance and antibody response in COVACTA were investigated.},
volume = {47},
journal = {EClinicalMedicine},
publisher = {Elsevier},
url = {http://dx.doi.org/10.1016/j.eclinm.2022.101409},
}
